VECTOR_DELIVERY

Scope

Programmable viral-vector delivery, payload delivery, targeting, manufacturing, and vector-platform strategy.

Core Platform

• Recombinant Sendai virus (rSeV).
• BiSeV / deleted Sendai architectures.
• CPIB3 as a Sendai-like vector under CAPTURE.
• Large-payload delivery.
• miRNA gating and cell-type-specific payload restriction.
• Base editing, prime editing, gene editors, scFvs, cytokines, and other therapeutic payloads.

Key Funding / Program Context

DARPA HERMES/CURES is centered on recombinant Sendai-virus-based delivery of therapeutic payloads. The project record remembers contract HR001124C0506, NYU-led CURES as “Customized Utility of Recombinant Sendai-based Vectors,” with tenOever, Boeke, and Lee labs; approximate period October 2024–September 2027; unclassified; approximately $3.5M. Verify formal details against executed award documents before formal use.

People

• Sydney Pimentel: miRNA ON-gates and SeV-R2/PRINT.
• Jonathan Dever: DARPA Sendai support and CPIB3/CAPTURE.
• Molly Durawa: in vivo vector support.
• Hedy Rocha: in vivo vector support.
• Raman Kaur: DARPA pilot experiments.
• Mark Chua: Sendai plaque quantification.
• Lucia Carrau: cross-project experimental support.

Major Subprojects

• DARPA CURES HERMES
• CAPTURE
• CPIB3 Vector
• miRNA ON Gates
• SeV R2 PRINT
• miRNA Gates

Methods

• Vector construction.
• In vivo biodistribution and payload activity.
• miRNA-targeting design.
• Prime/base editor delivery.
• Plaque-based quantification.
• Image-analysis workflows for R2-associated experiments.

Datasets / Artifacts

See VECTOR DELIVERY Datasets.

TODO

• Insert exact construct maps, vector backbones, payload sizes, rescue/manufacturing protocols, in vivo dosing, and validated tropism data when primary files are uploaded.